EUCTR2011-000509-29-GB进行中（未招募）1 期
A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of trastuzumab emtansine compared with treatment of physician’s choice in patients with HER2-positive metastatic breast cancer who have received at least two prior regimens of HER2-directed therapy. - TH3RESA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 602
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Age = 18 years
- •Histologically or cytologically documented breast cancer
- •Metastatic or unresectable locally advanced/recurrent breast cancer
- •HER2-positive disease by prospective central laboratory confirmation
- •Disease progression on the last systemic anti-cancer regimen received as defined by the investigator unless they were intolerant
- •Prior treatment with trastuzumab, lapatinib, and a taxane in any setting
- •Disease progression after at least two regimens of HER2 directed therapy in the metastatic or unresectable locally advanced/recurrent breast cancer
- •A minimum of 6 weeks of prior trastuzumab
- •Patients must have had at least 6 weeks prior exposure to lapatinib.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 540
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Chemotherapy = 21 days before first study treatment
- •Trastuzumab = 21 days before first study treatment
- •Lapatinib = 14 days before first study treatment
- •Prior enrollment in a trastuzumab emtansine-containing study, regardless of whether the patient received prior trastuzumab emtansine
- •Brain metastases that are untreated or symptomatic, or require any radiation, surgery, or corticosteroid therapy to control symptoms within 1 month of randomization.
研究者
相似试验
进行中（未招募）
不适用
An Open-Label Study of trastuzumab emtansine (T-DM1) compared to physician's choice in patients with HER2-Positive Metastatic Breast Cancer.Cáncer de Mama Metastásico HER2 positivo (CMM)MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000509-29-ESF. Hoffmann-La Roche Ltd795
进行中（未招募）
不适用
An Open-Label Study of trastuzumab emtansine (T-DM1) compared to physician's choice in patients with HER2-Positive Metastatic Breast Cancer.EUCTR2011-000509-29-SKF. Hoffmann-La Roche Ltd795
进行中（未招募）
1 期
An Open-Label Study of trastuzumab emtansine compared to physician's choice in patients with HER2-Positive Metastatic Breast Cancer.EUCTR2011-000509-29-CZF. Hoffmann-La Roche Ltd600
进行中（未招募）
不适用
An Open-Label Study of trastuzumab emtansine compared to physician's choice in patients with HER2-Positive Metastatic Breast Cancer.EUCTR2011-000509-29-HUF. Hoffmann-La Roche Ltd600
进行中（未招募）
1 期
An Open-Label Study of trastuzumab emtansine compared to physician's choice in patients with HER2-Positive Metastatic Breast Cancer.HER2-Positive Metastatic Breast Cancer (MBC)MedDRA version: 16.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-000509-29-NOF. Hoffmann-La Roche Ltd602